Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| As I mentioned previously, I think what we know, our performance for cabo in really all aspects, combination and monotherapy, is very strong in the community |
| We're pleased to see continued growth of the cabozantinib franchise in the U.S |
| And it's really early days from what we're observing there, but obviously, good news for patients with the potential to have those lower out-of-pocket costs |
| I won't reiterate everything here today but just focus on the top highlights including first, we saw a strong performance of the cabozantinib business in the fourth quarter and full year 2023 with continued growth in demand and revenue |
| With regards to the pembro adjuvant data, certainly impressive data in overall survival |
| Obviously, good to see an OS benefit for them there |
| And if there's more convenience for the overall regimen of cabo in combination with nivolumab for first-line RCC, that's certainly a good thing |
| So we're excited about the opportunity |
| And I think the way - I talked about this a bit before, the way we thought about it is really impressive data, great for patients |
| We think we have an opportunity for a best-in-class |
| And I would state that what we believe we have is a positive study in the ITT patient population and that this is the first positive global Phase 3 study of a TKI IO combination in metastatic castration-resistant prostate cancer patients who have progressed on at least one NHT in both pre-and post-chemo setting |
| We're super proud of all the work that we've done in collaboration with our commercial partners and our clinical partners on cabo |
| While we will not speak to any specifics today, I'm proud of the work that our team did preparing and presenting this case |
| Let me just take a step back and remind everybody what we're talking about with zanza is what we believe to be a best-in-class VEGFR TKI drug |
| We had a great year in 2023 and 2024 is shaping up to be an inflection point for the business, our science and the patients we hope to serve at an ever-expanding basis |
| It's hard to opine on the time lines, but we have some advantages with CABINET that we didn't have, for example, with Cabozan, most notably blinded independent central radiology review, was already incorporated into the study, and we do have a strong partnership with The Alliance |
| With regards to the subcu formulation, I think if there's more options for physicians and ultimately their patients, that's a positive thing |
| We are excited about the opportunity to move the company forward |
| But we are pretty confident that the combination that we're testing in head-and-neck with Zanza pem represent a pretty high probability of success |
| Also, it's really nice to see cabo's profound activity in the virtual metastases subgroup and cabo again in the prostate cancer space |
| But there's a reason to bring two potentially active agents together in this disease, and we're really excited about STELLAR-009 |
| So, I think that certainly could be, a nice opportunity for us should we be approved |
| First of all, we're really excited about the data and presenting it |
| So with regard to CABINET, we had some really exciting data |
| Fourth quarter cabo franchise net product revenues grew 14% year-over-year, compared to fourth quarter 2022 |
| Cabo franchise net product revenues grew 16% for full year 2023 compared to full year 2022 |
| And congratulations on achievements both in the clinical and financial fronts |
| Third, we made significant progress in advancing the pipeline in 2023 that was highlighted at our R&D Day presentation in December |
| I want everyone to know that our team is highly motivated every single day to excel on our mission to help cancer patients recover stronger and live longer |
| Exelixis had a strong year in 2023 and we're already sprinting into 2024 after a busy January where we provided important updates across literally all components of our business |
| Statement |
|---|
| We know that the LEAP study was negative, and obviously, we're going to review the data very carefully once it's public to assess what if any modifications need to be made in 305, but I think what we've also observed with the combination of pem len is the difficulty that physicians are having with regard to maintaining dose density of len |
| Finally, clinical trial sales have historically been choppy between quarters and we expect this to continue in future quarters |
| Access to radioligand therapy, is not as ubiquitous there, and when you talk to physicians, clinicians, offices, it can potentially mean losing the patient, and some opportunity there |
| We have a patient population that has a very poor prognosis that, was observed in the median time to progression on placebo of three months change to 8.3 and 11.4 months, depending on whether or not you had pNET or epNET |
| We delayed time to chemotherapy with Cabo-Atezo |
| I think you might be referring to the recently reported failure of pem len in this setting |
| We refer you to the documents we file from time-to-time with the SEC, which under the heading Risk Factors identify important factors that could cause actual results to differ materially from those expressed in by the company verbally and in writing today, including, without limitation, risks and uncertainties related to product commercial success, market competition, regulatory review and approval processes, conducting clinical trials, compliance with applicable regulatory requirements, our dependence on collaboration partners, and the level of costs associated with discovery, product development, business development and commercialization activities |
| The five-year overall survival rate for this population is still only 15% |
| R&D expense was the primary driver of the decline in total operating expenses, which was primarily related to lower licensing expenses |
| And so delaying time to chemotherapy is not a bad thing |
| Both of these therapies, obviously have limitations, whether it's RLT with regards to logistics, issues in terms of what that means for the patient with regards to being around family, et-cetera |
| And when you have enough dose reductions that act -- that actually can interfere with the activity profile and could be a big reason why this doublet may not have succeeded but where Zanza pem could succeed |
Please consider a small donation if you think this website provides you with relevant information